Format

Send to

Choose Destination
Oncotarget. 2016 Aug 16;7(33):53127-53136. doi: 10.18632/oncotarget.10634.

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.

Author information

1
INSERM, U976, Skin Research Centre, Hôpital Saint-Louis, Paris, F-75010, France.
2
Université Paris Diderot, Sorbonne Paris Cité, UMRS976, Paris, F-75010, France.
3
Department of Internal Medicine, School of Medicine Sciences, State University of Campinas (UNICAMP), 13083-970, Campinas, SP, Brazil.
4
Division of Molecular Genetic Epidemiology, German Cancer Research Center, 69120 Heidelberg, Germany.

Abstract

The mechanism of telomerase re-activation in cancer had remained elusive until the discovery of frequent mutations in the promoter of the TERT gene that encodes the catalytic reverse transcriptase subunit of telomerase. We investigated the regulation of TERT expression in melanoma cell lines and our results show that promoter mutations render TERT expression dependent on MAPK activation due to oncogenic BRAF or NRAS mutations. Mutations in the TERT promoter create binding sites for ETS transcription factors. ETS1, expressed in melanoma cell lines, undergoes activating phosphorylation by ERK at Thr38 residue as a consequence of constitutively activated MAPK pathway. We demonstrate that ETS1 binds on the mutated TERT promoter leading to the re-expression of the gene. The inhibition of ETS1 resulted in reduced TERT expression. We provide evidence that the TERT promoter mutations provide a direct link between TERT expression and MAPK pathway activation due to BRAF or NRAS mutations via the transcription factor ETS1.

KEYWORDS:

BRAF; ETS1; MAPK pathway; melanoma; telomerase

PMID:
27449293
PMCID:
PMC5288173
DOI:
10.18632/oncotarget.10634
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center